About Us

The Center for Personalized Cancer Therapy (CPCT) is a joint program of the University of Massachusetts Boston and the Dana Farber/Harvard Cancer Center (DF/HCC).

The goals of the center are to:

  1. Create research support platforms to facilitate high impact translational cancer research (academic and startup biotech companies).
  2. Focus research efforts on the development, validation, and commercialization of RNA- and protein-based cancer biomarkers with significant clinical utility: tumor subtyping and early measures of tumor response to therapy.
  3. Train and bring diverse student talent into DF/HCC.
  4. Provide UMass Boston students with skills suitable for academic careers or employment in regional biomedical industry.

The CPCT will provide a means for undergraduate and graduate students to become the next generation of well-trained biomedical workforce talent and the future leaders of life sciences research in academia and industry. 

A scientific focus of the center is cancer health disparities research.  The National Cancer Institute (NCI) defines "cancer health disparities" as adverse differences in cancer incidence (new cases), cancer prevalence (all existing cases), cancer death (mortality), cancer survivorship, and burden of cancer or related health conditions that exist among specific population groups in the United States. The CPCT seeks to understand the pathobiologies that drive cancer health disparities and to apply this knowledge to improve cancer treatment in affected populations. 

Learn more about the CPCT

Check out our presentation!
Read More

CPCT in the Mass Media News

Read More

CPCT in The RISC Quarterly

Read More

Center for Personalized Cancer Therapy

100 Morrissey Blvd.
Boston, MA 02125-3393 USA